Plain-English translation of NCT07755826 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a safety monitoring study for children and teenagers in Japan who are being treated with for a rare type of cancer called NTRK fusion-positive solid tumors. Instead of testing a new drug, researchers will watch how well the medication works and what side effects patients experience during their regular medical care. The study is especially interested in watching for three types of side effects: problems affecting the brain and nervous system, lung problems, and bone fractures.
is a newer medication for rare childhood cancers, and doctors need to gather real-world information about how safe it is when patients use it in everyday medical practice. By collecting this safety information, researchers can better understand how to protect children from potential complications and help doctors use the treatment more safely.
You likely qualify if…
You likely don't qualify if…
You would not need to do anything extra beyond your regular cancer treatment visits. Researchers will collect information about your health and any side effects you experience as part of your normal medical care at your hospital or clinic in Japan. This safety monitoring will continue for up to 6 years after the medication is approved.
AI-generated summary from trial data · Oct 7, 2026 · Not medical advice
Japan
Sponsor
Bristol-Myers Squibb
Enrollment target
~20 participants
Started
November 2025
Primary completion
April 2034
Age range
4 Years – 17 Years
Last updated on clinicaltrials.gov in August 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Bristol-Myers Squibb
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.